Walleye Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$81.5K Sell
2,800
-3,800
-58% -$101K ﹤0.01% 5269
2026
Q2
$119K Buy
6,600
+4,800
+267% +$74.2K ﹤0.01% 3802
2026
Q1
$25K Sell
1,800
-7,100
-80% -$100K ﹤0.01% 4042
2025
Q4
$108K Buy
8,900
+2,100
+31% +$28.5K ﹤0.01% 3841
2025
Q3
$92.4K Buy
+6,800
New +$64K ﹤0.01% 3739
2025
Q1
– Sell
-33,500
Closed -$127K – 4205
2024
Q4
$127K Buy
+33,500
New +$158K ﹤0.01% 4019
2024
Q2
– Sell
-100
Closed -$284 – 5548
2024
Q1
$284 Buy
+100
New +$1.31K ﹤0.01% 5348
2023
Q4
– Sell
-1,800
Closed -$33K – 4901
2023
Q3
$33K Buy
+1,800
New +$38.1K ﹤0.01% 4295
2023
Q1
– Sell
-6,700
Closed -$248K – 3898
2022
Q4
$248K Buy
+6,700
New +$238K ﹤0.01% 1908

Other funds holding AMLX

Walleye Capital's AMLX Position: Q3 2026 in Review

Walleye Capital reduced its Amylyx Pharmaceuticals (AMLX) stake by 100% in Q3 2026, selling an estimated $4.93M and leaving 767 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5632.

Walleye Capital first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $8.58M in Q4 2023. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Walleye Capital held 767 shares of Amylyx Pharmaceuticals worth $22.3K as of Q3 2026.
  • Walleye Capital sold 185,821 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $4.93M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5632 holding.
  • Walleye Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Walleye Capital's Amylyx Pharmaceuticals position peaked at $8.58M in Q4 2023.
  • 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.